Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunjan Shah

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2026
Respiratory Syncytial Virus After CAR T-cell therapy: Risk Factors and Outcomes in a Multicenter Retrospective CohortMaria Isabel Sotelo-Alva, Ofrat Beyar-Katz, Judy Yan, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Research Square|July 16, 2024
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaJae Park, M Lia Palomba, Karlo Perica, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2025
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell LymphomaJae H Park, M Lia Palomba, Karlo Perica, et al.
Transplantation and Cellular Therapy|April 6, 2026
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell LymphomaSilvia Escribano Serrat, Andrew Ip, Jaime Sanz, et al.
Cancer|September 23, 2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myelomaPashna N Munshi, David Vesole, Artur Jurczyszyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2022
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based DietsUrvi A Shah, Kylee H Maclachlan, Andriy Derkach, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.
Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2026
Respiratory Syncytial Virus After CAR T-cell therapy: Risk Factors and Outcomes in a Multicenter Retrospective CohortMaria Isabel Sotelo-Alva, Ofrat Beyar-Katz, Judy Yan, et al.
Blood Advances|October 1, 2020
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapiesDavid Sermer, Connie Batlevi, M Lia Palomba, et al.
Research Square|July 16, 2024
Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell LymphomaJae Park, M Lia Palomba, Karlo Perica, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2025
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell LymphomaJae H Park, M Lia Palomba, Karlo Perica, et al.
Transplantation and Cellular Therapy|April 6, 2026
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell LymphomaSilvia Escribano Serrat, Andrew Ip, Jaime Sanz, et al.
Cancer|September 23, 2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myelomaPashna N Munshi, David Vesole, Artur Jurczyszyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2022
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based DietsUrvi A Shah, Kylee H Maclachlan, Andriy Derkach, et al.
Pageof 6